Antituberculosis drugs and hepatotoxicity
نویسندگان
چکیده
منابع مشابه
Antituberculosis drugs and hepatotoxicity.
Isoniazid, pyrazinamide and rifampicin have hepatotoxic potential, and can lead to such reactions during antituberculosis chemotherapy. Most of the hepatotoxic reactions are dose-related; some are, however, caused by drug hypersensitivity. The immunogenetics of antituberculosis drug-induced hepatotoxicity, especially inclusive of acetylaor phenotype polymorphism, have been increasingly unravell...
متن کاملHepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis.
Hepatotoxicity due to antituberculosis drugs limits treatment in patients coinfected with HIV and tuberculosis. We conducted a case-control study to identify risk factors for hepatotoxicity among patients coinfected with tuberculosis and HIV in two hospitals in Recife, Pernambuco State, Brazil. The sample consisted of 57 patients (36.5% of the total) who developed hepatotoxicity and a control g...
متن کاملAntituberculosis drug-induced hepatotoxicity in children
Recent increases in the dosages of the essential antituberculosis agents isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA) for use in children recommended by World Health Organization have raised concerns regarding the risk of hepatotoxicity. Published data relating to the incidence and pathogenesis of antituberculosis drug-induced hepatotoxicity (ADIH), particularly in children, is reviewe...
متن کاملRisk factors for hepatotoxicity from antituberculosis drugs: a case-control study.
BACKGROUND Several risk factors for the development of hepatotoxicity during short course antituberculosis therapy have been suggested. A case-control study was undertaken to assess the role of age, sex, disease extent, nutritional status, past history of liver disease, infection with hepatitis viruses, acetylator status, and high alcohol intake as risk factors in the development of hepatotoxic...
متن کاملHepatotoxicity and antituberculosis therapy: time to revise UK guidance?
REFERENCES 1. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322–9. 2. Bayer. VENTAVIS Consumer Medicine Information Leaflet. Bayer HealthCare, Bayer Schering Pharma. http://www.bayer.com.au/html/images/upload/CMIs/ 080424_Ventavis_CMI_ANZ.pdf (accessed 30 Jan 2009). 3. Beghetti M, Reber G, de MP, et al. Aerosolized iloprost ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Respirology
سال: 2006
ISSN: 1323-7799,1440-1843
DOI: 10.1111/j.1440-1843.2006.00941.x